J P Rybicki, G C Le Breton
Index: Thromb. Res. 30(5) , 407-14, (1983)
Full Text: HTML
In the present study we investigated the ability of prostaglandin H2 (PGH2) to lower platelet cAMP levels independent of thromboxane A2 (TXA2) production. Human platelet-rich plasma was incubated (37 degrees C) with 13 nM prostacyclin (PGI2) to increase platelet cAMP levels. Addition of 500 microM arachidonic acid (AA) to PGI2-treated platelets resulted in a return of cAMP to control levels. Inhibition of both PGH2 and TXA2 production with indomethacin (20 microM) blocked the ability of AA to lower PGI2-stimulated increases in cAMP. On the other hand, selective inhibition of TXA2 production with the thromboxane synthetase blocker 7-(1 imidazoyl) heptanoic acid (7-IHA; 10 microM), did not prevent the cAMP lowering effect of added AA. These results provide evidence that PGH2 need not be converted to TXA2 in order to reduce platelet cAMP levels.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Prostaglandin H2
CAS:42935-17-1 |
C20H32O5 |
What we know about primary dysmenorrhea today: a critical re...
2015-01-01 [Hum. Reprod. Update 21 , 762-78, (2015)] |
Anti-peptide antibodies against the human blood platelet thr...
1993-05-25 [Biochem. Pharmacol. 45(10) , 2071-8, (1993)] |
Evidence for coordinate, selective regulation of eicosanoid ...
1988-12-25 [J. Biol. Chem. 263(36) , 19384-91, (1988)] |
Prostaglandin endoperoxides and thromboxane A2 activate the ...
2002-01-01 [Thromb. Haemost. 87(1) , 114-21, (2002)] |
Levuglandins and isolevuglandins: stealthy toxins of oxidati...
2005-01-01 [Antioxid. Redox Signal. 7(1-2) , 185-201, (2005)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved